Support Our Work: To keep this global epidemiological tracker 100% free and continuously updated, we rely on advertisements. We apologize for any inconvenience.
Google Ads Space (Leaderboard 728x90)
TRAVEL ADVISORY: WHO issues monitoring alert for recent passengers of MV Hondius.

2025–2026 ANDV Outbreak Tracker

Comprehensive real-time tracking of the Andes Orthohantavirus (ANDV) cluster. Aggregating verified data from public health agencies, maritime AIS tracking, and global news streams.

48Suspected Cases
12Confirmed Positive
4Deceased
8Endemic Zones

Live Epidemiological Map

Live Sync
Active Outbreak Monitored Cases
Google Ads Space (In-feed Responsive)

Outbreak Timeline & Case Logs

Chronological tracking of verified patient reports.

Suspected

Case #26 - Alicante, Spain

Onset: May 7, 2026. Patient was a passenger on the April 24th transfer flight. Currently isolated and undergoing PCR testing.

Suspected

Case #11 - Singapore (67 ♂)

Onset: May 6, 2026. Awaiting test results at NCID. Traveled on the same flight from St Helena to Johannesburg.

Monitoring

Case #10 - Netherlands (♀)

Onset: May 6, 2026. Airline flight attendant, highly symptomatic but laboratory confirmation is pending.

Confirmed

Case #5 - Zurich (♂)

Onset: May 6, 2026. Successfully departed ship early, confirmed positive via serology in Switzerland.

Deceased

Case #4 - MV Hondius (🇩🇪)

Onset: Apr 24, 2026. German National. Developed severe HPS (Hantavirus Pulmonary Syndrome) and passed away May 2, 2026.

Confirmed

Case #3 - MV Hondius (🇳🇱)

Onset: Apr 20, 2026. Dutch National. Evaluated by ship's medical officer for persistent high fever and myalgia. PCR testing positive for ANDV.

Deceased

Case #2 - MV Hondius (🇬🇧)

Onset: Apr 18, 2026. British National. Rapid pulmonary deterioration within 48 hours of initial symptom presentation. Expiration recorded on Apr 22, 2026.

Index Case

Case #1 - MV Hondius (🇦🇷)

Onset: Apr 15, 2026. Suspected exposure in Ushuaia prior to embarkation. Patient zero for the onboard cluster.

Vessel: MV Hondius

En route to Tenerife, Canary Islands

The expedition vessel has been placed under maritime quarantine protocols due to the identification of the ANDV strain.

AIS Status: Navigating (147 onboard)
Deceased on board: 4 total
Crew Isolated: Yes
View Full AIS Dashboard →

Regional Distribution

  • Netherlands4 cases
  • St Helena4 cases
  • Canada3 cases
  • Zurich2 cases
  • Johannesburg2 cases
  • Singapore2 cases

Live News Stream

Auto-updating
Fetching live global news...

Prevention & Global Response Protocols

1. Individual Prevention Strategies

Preventing Hantavirus infection primarily involves minimizing contact with rodents and their habitats. In areas endemic to hantavirus carriers, it is critical to keep food sealed, dispose of waste properly, and ensure that living quarters are rodent-proof. If cleaning areas where rodents have been present, use a disinfectant (such as a diluted bleach solution) to wet the area before cleaning to prevent the virus from becoming aerosolized.

2. Maritime & Aviation Bio-Security

The MV Hondius incident has highlighted the need for rigorous maritime bio-security protocols. Ships traveling through endemic zones must implement strict pest control and monitor crew and passengers for early onset respiratory symptoms. In cases of suspected ANDV, rapid isolation and dedicated ventilation management are essential to mitigate the risk of secondary transmission among the vessel's population.

3. International Surveillance Networks

The Global Outbreak Alert and Response Network (GOARN) is currently monitoring the situation in real-time. By aggregating data from local health departments and international laboratories, GOARN provides a unified operational framework for responding to such clusters. This dashboard serves as a public-facing window into these surveillance efforts, aiming to increase transparency and public awareness during ongoing outbreaks.

4. Research, Diagnostics & Future Vaccines

Diagnostic capabilities for ANDV have improved significantly with the advent of rapid PCR testing. However, there is currently no FDA-approved vaccine for Hantavirus Pulmonary Syndrome. Research is ongoing into DNA-based vaccines and monoclonal antibody treatments that could potentially neutralize the virus during the early stages of infection. Global cooperation in viral genomic sequencing is vital for identifying potential mutations in the ANDV strain that could impact its transmissibility.

Understanding the MV Hondius Incident

In April 2026, health authorities identified an unprecedented cluster of respiratory illness aboard the expedition cruise ship MV Hondius. Initial testing confirmed the presence of the Andes Orthohantavirus (ANDV), a rare pathogen native to South America.

The situation aboard the MV Hondius expedition vessel represents a critical epidemiological event due to the specific viral strain identified: the Andes Orthohantavirus (ANDV). Unlike most hantaviruses, which are exclusively contracted through the inhalation of aerosolized rodent excreta (primarily from the long-tailed pygmy rice rat in South America), ANDV is the only known hantavirus capable of human-to-human transmission. This rare transmission vector drastically changes the risk profile in enclosed environments such as cruise ships, where ventilation systems and close-quarter interactions can accelerate viral spread.

The ship is currently navigating toward Tenerife, Canary Islands under strict maritime quarantine protocols. International health organizations, including the WHO and ECDC, are coordinating with Spanish health authorities to ensure a safe transition for those requiring advanced medical care while maintaining isolation for the remaining 147 individuals onboard.

Clinical Overview: Hantavirus Pulmonary Syndrome (HPS)

Hantavirus Pulmonary Syndrome (HPS) is a severe, sometimes fatal, respiratory disease in humans caused by infection with hantaviruses. Early symptoms are notoriously non-specific and mimic severe influenza, including fatigue, fever, and muscle aches (especially in large muscle groups like thighs, hips, and back). Roughly half of HPS patients also experience headaches, dizziness, chills, and abdominal pain, such as nausea, vomiting, and diarrhea.

Four to ten days after the initial phase of illness, the late symptoms of HPS emerge. These include coughing and extreme shortness of breath, as the lungs fill with fluid—a condition known as noncardiogenic pulmonary edema. The mortality rate for HPS is exceptionally high, historically estimated at 38%, requiring immediate intensive care intervention, mechanical ventilation, and oxygen therapy.

Frequently Asked Questions (FAQ)

Can ANDV spread from person to person?

Yes. While most hantaviruses only spread through rodent contact, the Andes virus (ANDV) strain found in South America and the current MV Hondius cluster has been documented to spread through close personal contact. This is why strict quarantine and contact tracing are essential.

What is the survival rate for Hantavirus?

Hantavirus Pulmonary Syndrome (HPS) is a severe disease with a high mortality rate, historically around 38%. However, with modern intensive care, early detection, and mechanical ventilation support, the prognosis can improve. There is currently no specific antiviral cure; treatment is primarily supportive.

How long is the incubation period?

The time between exposure and the first symptoms typically ranges from 1 to 8 weeks, with an average of about 2 to 3 weeks. In the case of the ANDV strain, monitoring protocols often extend up to 36 or 40 days to be absolutely certain of safety.

Is there a vaccine for Hantavirus?

No, there is currently no FDA-approved vaccine for any hantavirus strain in Western countries. Some countries in Asia use vaccines for different strains (like Hantaan virus), but they are not effective against the ANDV strain identified in this outbreak.